Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sobetirome (IACS-010759) is a selective agonist of thyroid hormone receptor β (TRβ) and binds selectively to TRβ-1 (EC50: 0.16 μM).
説明 | Sobetirome (IACS-010759) is a selective agonist of thyroid hormone receptor β (TRβ) and binds selectively to TRβ-1 (EC50: 0.16 μM). |
ターゲット&IC50 | TRα 1:0.58 μM (EC50), TRβ 1:0.16 μM (EC50) |
In vitro | GC-1 was designed to bind selectively to TRβ (EC50: 0.58 μM for TRα-1, 0.16 μM for TRβ-1) [1]. The thyromimetic agent GC-1 induces hepatocyte proliferation via Wnt/β-catenin signaling and may promote regeneration in both acute and chronic liver insufficiencies [2]. |
In vivo | Four weeks following injection, mice were fed 5 mg/kg GC-1 or basal diet for 10 or 21 days. Treatment with GC-1 for 10 or 21 days led to a significant reduction in tumor burden [2]. GC-1 treatment reduced serum cholesterol levels by 25% and serum triglycerides by 75% in chow-fed mice and also attenuated diet-induced hypercholesterolemia [3]. GC-1 (50 or 100 mug/100 g body weight) strongly stimulates rat hepatocyte proliferation in the absence of tissue injury. GC-1 also induced massive pancreatic cell proliferation [4]. |
動物実験 | Briefly, 20 μg of a pT3-EF5α-hMet-V5 and pT3-EF5α-S45Y-β-catenin-Myc combination along with the transposase in a ratio of 25:1 were diluted in 2 mL of normal saline (0.9% NaCl), filtered through a 0.22-μm filter, and injected into the lateral tail vein of 23 FVB mice that were around 6 weeks old, in 5 to 7 seconds. These mice are referred henceforth as hMet-mutant-β-catenin mice. Four weeks after injection, hMet-mutant-β-catenin mice were randomized into two groups. One group was kept on a basal diet (n = 12), and another group was switched to a GC-1–supplemented diet (5 mg/kg of diet) (n = 11). Animals on control diet were sacrificed at either 21 days (n = 8) or 10 days (n = 4) after initiation of the diet. Similarly, animals on the GC-1 diet were sacrificed at either 21 days (n = 7) or 10 days (n = 4) after initiation of the diet. The animals were given access to food and water ad libitum with a 12-hour light/dark daily cycle. One intraperitoneal injection of bromodeoxyuridine (BrdU) was performed on day 9 during 10 days of GC-1 or basal diet treatment, and livers were harvested 24 hours later [2]. |
別名 | IACS-010759, QRX-431 |
分子量 | 328.4 |
分子式 | C20H24O4 |
CAS No. | 211110-63-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (91.4 mM)
Ethanol: 30 mg/mL
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sobetirome 211110-63-3 Endocrinology/Hormones Thyroid hormone receptor(THR) QRX431 Inhibitor IACS010759 IACS-010759 GC1 inhibit QRX-431 IACS 010759 Thyroid Hormone Receptor QRX 431 GC-1 GC 1 THR inhibitor